HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Gestodene

synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer

Also Known As:

13-ethyl-17-hydroxy-18,19-dinor-17 alpha-pregna-4,15-dien-20-yn-3-one; 17-alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one; Gestoden; Gestodene, ((17alpha)-(+-))-isomer; SH B 3331; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-

Networked: 152 relevant articles (2 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 56
- Steroids: 18537
  - Norsteroids: 12
    - Norpregnanes: 1
      - Norpregnenes
        Gestodene: 152

Experts

1.	Maia, Hugo: 6 articles (01/2014 - 10/2006)
2.	Casoy, Julio: 6 articles (01/2014 - 10/2006)
3.	Lidegaard, Øjvind: 4 articles (10/2014 - 01/2009)
4.	Rosendaal, Frits R: 4 articles (01/2014 - 05/2002)
5.	Helmerhorst, Frans M: 4 articles (01/2014 - 05/2002)
6.	Løkkegaard, Ellen: 3 articles (06/2012 - 01/2009)
7.	Correia, Tânia: 3 articles (04/2010 - 10/2006)
8.	Athayde, Célia: 3 articles (04/2010 - 10/2006)
9.	Helmerhorst, F M: 3 articles (01/2009 - 08/2002)
10.	Merz, M: 2 articles (02/2015 - 02/2015)

Related Diseases

1.	Metrorrhagia (Spotting) 01/01/1987 - "In the total number of gestodene cycles in studies A and B, there was a 6.9% incidence of spotting, a 0.8% incidence of breakthrough bleeding, and a 0.7% incidence of both spotting and breakthrough bleeding in studies A and B patients taking gestodene. " 01/01/2011 - "She referred with metrorrhagia of about one year, and was being treated with Ethynylestradiol/Gestodene. " 10/01/1995 - "With respect to cycle control, there is a trend towards a lower incidence of intermenstrual bleeding in the gestodene group. " 09/01/1994 - "Gestodene group exhibited significantly better cycle control as evidenced by the lower incidence of breakthrough bleeding and spotting. " 10/01/1993 - " On the other hand, breakthrough bleeding occurred less often in women in the gestodene group (19.3% vs. 29.6%). "
2.	Endometriosis (Adenomyosis) 03/01/2008 - "Endometrial biopsies were taken at the time of laparoscopy in 40 patients with endometriosis, 16 of whom were using an oral contraceptive containing gestodene at the time of laparoscopy. " 03/01/2008 - "Oral contraceptives containing gestodene are effective in decreasing aromatase expression in the eutopic endometrium of patients with endometriosis." 01/01/2012 - "After a conservative surgery, 84 patients with symptomatic endometriosis were randomized to receive either intramuscular DMPA (150 mg) every 12 weeks for 24 weeks or continuous OC pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks. " 03/01/2008 - "To determine the effect of oral contraceptives containing gestodene on aromatase expression in the endometrium of patients diagnosed with endometriosis. " 10/01/2006 - "This was a retrospective cohort study carried out in paraffin-embedded endometrial tissue obtained from patients with a histological diagnosis of adenomyosis obtained during the proliferative (n = 25) and luteal (n = 10) phases of the menstrual cycle and following the use of continuous oral contraception with gestodene/ethinyl estradiol (n = 7). "
3.	Venous Thromboembolism 05/01/2010 - "Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare"." 11/01/1999 - "The warning issued by the UK Committee on Safety Medicines in October 1995, followed by their 'Dear Doctor' letter of October 18, 1995, that oral contraceptive pills containing gestodene or desogestrel were associated with a higher risk of venous thromboembolism has had a negative impact on public heath. " 11/08/1996 - " In New Zealand, about 75% of OC users (compared to 50% in the UK) use these new OCs and about 40 of the 50 expected cases of venous thromboembolism in New Zealand pill users per year will occur in women taking OCs containing desogestrel or gestodene." 11/08/1996 - " In 1995, the UK Committee on the Safety of Medicines advised physicians not to prescribe OCs containing desogestrel or gestodene to women with risk factors for venous thromboembolism and recommended that current users should continue with these preparations only if they could not tolerate other OCs. " 09/01/1998 - " The adjusted odds ratios in the UK study did not show any significant increases in venous thromboembolism risk for desogestrel or gestodene compared with levonorgestrel. "
4.	Hemorrhage 04/01/2007 - "This is in contrast to regimens containing gestodene, where smoking women are less likely to differ from non-smoking women with regard to bleeding. " 04/01/2000 - "The latent period before withdrawal bleeding was significantly longer for monophasic gestodene at cycles 1-5 and 8-10 (p < 0.05). " 03/01/1994 - "Significantly less bleeding was seen in the gestodene group during cycle 2 (p = 0.02). " 10/01/1995 - "The incidence of spotting (scanty bleeding) during the important first three cycles was 3.5% lower in the gestodene group, and over the first six cycles, it was 7.6% lower. " 10/01/1992 - "In contrast, clinical tolerance with the new progestins such as gestodene is good; in one study 86% of patients had normal bleeding patterns. "
5.	Body Weight (Weight, Body) 12/01/2001 - "Data on body weight were retrospectively analyzed from four large prospective clinical trials with an oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene (EE/GSD). " 01/01/1987 - "Body weight remained unchanged (+/- 2 kg) after 24 cycles in 80.5% of study B patients taking gestodene. " 01/01/2003 - "[Effect and control of oral contraceptive Minesse (15 mkg EE/60 mkg Gestoden) on menstrual cycle and body weight]." 12/01/2001 - "This retrospective analysis confirms that there was only a negligible change of body weight during intake of an oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene. " 12/01/2001 - "We found no clinically relevant change of body weight during treatment with an oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene in the vast majority of users after 12 treatment cycles. "

Related Drugs and Biologics

1.	Oral Contraceptives
2.	Aromatase (CYP19)
3.	felbamate (Felbatol)
4.	Desogestrel
5.	Progestins (Progestagens)
6.	Ethinyl Estradiol (Estinyl)
7.	Levonorgestrel (Plan B)
8.	drospirenone
9.	Sex Hormone-Binding Globulin
10.	norgestimate

Related Therapies and Procedures

1.	Contraception (Birth Control)
2.	Stents
3.	Female Contraceptive Devices (Vaginal Ring)
4.	Oral Administration